Lewis G C, Blessing J
Cancer. 1977 Jul;40(1 Suppl):588-94. doi: 10.1002/1097-0142(197707)40:1+<588::aid-cncr2820400725>3.0.co;2-8.
Appreciating the past reports of effectiveness for various therapeutic modalities in ovarian cancer, the Gynecologic Oncology Group activated eight protocols. Three involved epithelial lesions with randomized multimodality trials alone or in combination. The other protocols were devoted to registration of rare tumor case reports. Conclusions are still difficult to reach due to inconsistencies in pathologic diagnoses and deficiencies in radiation therapy, chemotherapy and surgery inherent in the initial phases of group development by diverse specialist in oncology. Adjuvant therapy for early cancer seems to have no advantage. Single drug, melphalan therapy may be as effective as multi-drug, irradiation or combined drug-irradiation therapy and less toxic. For the rare tumors, preliminary results suggest therapeutic advantage for at least one triple drug program in malignant teratoma. With the lessons of the past, it is anticipated that new studies briefly described herewith may be more effectively applied.
鉴于过去有关卵巢癌各种治疗方式有效性的报告，妇科肿瘤学组启动了八项方案。其中三项涉及上皮性病变，采用单独或联合的随机多模式试验。其他方案则致力于罕见肿瘤病例报告的登记。由于病理诊断不一致以及肿瘤学领域不同专家在该组发展初期放疗、化疗和手术方面存在缺陷，目前仍难以得出结论。早期癌症的辅助治疗似乎并无优势。单药美法仑治疗可能与多药、放疗或联合药物放疗治疗效果相同，但毒性更小。对于罕见肿瘤，初步结果表明至少一种三联药物方案对恶性畸胎瘤具有治疗优势。吸取过去的经验教训，预计此处简要描述的新研究可能会得到更有效的应用。
